NKP-1339 is primarily investigated for its potential application in cancer treatment. It functions as a ruthenium-based compound that has shown promise in targeting tumor cells while minimizing damage to healthy tissues. The compound is believed to interact with cellular proteins and DNA, disrupting cancer cell proliferation and inducing apoptosis. Its selective action makes it a candidate for treating various types of cancers, particularly those resistant to traditional chemotherapy. Clinical trials are ongoing to evaluate its efficacy, safety, and optimal dosing in human patients. Additionally, research explores its potential in combination therapies to enhance overall treatment outcomes.